{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-043538","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.863777+00:00","generated_at":"2026-06-19T06:25:09.066407+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Edwards Lifesciences amends bylaws to adopt universal proxy rules and update advance notice provisions","bullets":["Bylaws amended to incorporate Rule 14a-19 universal proxy requirements for director nominations.","Stockholders must provide evidence of compliance with universal proxy rules, including soliciting at least 67% voting power.","Advance notice provisions updated with additional disclosure requirements for nominees and proposing stockholders.","Company may require proposed nominees to submit to interviews with the Board or a committee.","Other technical and conforming changes to align with recent amendments to Delaware General Corporation Law."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-043538","json":"https://secwatch.observer/filing/0001193125-23-043538.json","markdown":"https://secwatch.observer/filing/0001193125-23-043538.md","text":"https://secwatch.observer/filing/0001193125-23-043538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000119312523043538/0001193125-23-043538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000119312523043538/d452156d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:25:09.066407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34e09da4b0778970c928f0450208f775634c5a1b","claim":"Edwards Lifesciences Corp: Amended and restated Bylaws to incorporate universal proxy rule (Rule 14a-19) and update advance notice provisions for director nominations, including new disclosure and compliance requirements (effective 2023-02-16).","evidence_excerpt":"On February 16, 2023, the Board of Directors (the “Board”) of Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), amended and restated the Company’s Bylaws (as so amended and restated, the “Bylaws”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000119312523043538/0001193125-23-043538-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-02-16"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}